Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 74.68M | $ 58.84M | $ 43.88M | $ 39.68M | $ 10.00M |
| Gross Profit | $ 3.73M | $ 13.60M | $ 1.29M | $ -8.59M | $ 10.00M |
| Operating Income | $ -648.13M | $ -479.00M | $ -350.06M | $ -245.73M | $ -182.78M |
| EBITDA | $ -561.19M | $ -426.72M | $ -307.63M | $ -227.66M | $ -175.12M |
| Net Income | $ -644.76M | $ -463.66M | $ -328.07M | $ -239.48M | $ -186.48M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 743.29M | $ 594.35M | $ 391.56M | $ 549.91M | $ 516.56M |
| Total Assets | $ 1.47B | $ 1.45B | $ 653.70M | $ 701.29M | $ 610.35M |
| Total Debt | $ 77.97M | $ 108.49M | $ 50.67M | $ 51.01M | $ 11.48M |
| Net Debt | $ -665.33M | $ -485.86M | $ -340.89M | $ -498.91M | $ -273.64M |
| Total Liabilities | $ 343.26M | $ 413.82M | $ 190.26M | $ 215.48M | $ 67.41M |
| Stockholders' Equity | $ 1.13B | $ 1.03B | $ 463.44M | $ 485.81M | $ 542.94M |
| Cash Flow | |||||
| Free Cash Flow | $ -378.28M | $ -372.87M | $ -300.33M | $ -120.88M | $ -198.41M |
| Operating Cash Flow | $ -371.81M | $ -359.17M | $ -287.78M | $ -83.52M | $ -158.61M |
| Investing Cash Flow | $ -16.87M | $ 260.06M | $ -10.23M | $ 193.25M | $ -271.74M |
| Financing Cash Flow | $ 521.53M | $ 304.12M | $ 140.13M | $ 154.34M | $ 458.54M |